Methylfolate.

Methylfolate donates its methyl group to homocysteine to rebuild methionine, and the enzyme for that step, methionine synthase, only works with vitamin B12 sitting in it as the cofactor. Because folate on its own can mask a low B12 status, the two are routinely paired so the methylation cycle keeps turning.

Betaine drives a second, folate-independent route that turns homocysteine back into methionine, run by the enzyme BHMT in the liver. It works alongside the methylfolate pathway, giving the body two complementary ways to keep homocysteine moving through the methylation cycle.

Riboflavin supplies FAD, the flavin cofactor the enzyme MTHFR needs to build methylfolate in the body. When riboflavin runs low that step slows and less methylfolate reaches the rest of the cycle, so the two support the same one-carbon machinery from different points.

Where methylfolate helps recycle homocysteine back into methionine, vitamin B6 as pyridoxal-5-phosphate powers the other exit, the transsulfuration route that moves homocysteine on toward cysteine. Pairing them supports homocysteine metabolism from both sides, which is why folate and B6 sit together in most one-carbon formulas.

Serine hydroxymethyltransferase moves a one-carbon unit from serine onto tetrahydrofolate, the main entry point for carbon into the folate cycle. Serine supply therefore sets how much methylfolate the cycle can generate.

The glycine cleavage system hands a one-carbon unit to tetrahydrofolate, and glycine is also the acceptor that offloads surplus methyl groups from S-adenosylmethionine. Both reactions sit directly either side of the methylfolate step.

Methylfolate donates its methyl group to homocysteine to form methionine, which is then activated to S-adenosylmethionine. The two sit in one loop, and S-adenosylmethionine in turn slows the folate cycle by inhibiting the enzyme that makes methylfolate.

Choline oxidised to betaine offers a second route for methylating homocysteine that runs independently of folate. Adequate choline spares methylfolate for other one-carbon work such as nucleotide synthesis.

TMG methylates homocysteine through betaine-homocysteine methyltransferase, running alongside the folate and cobalamin route. Pairing them keeps homocysteine remethylation covered when either pathway is running slowly.

Betaine-homocysteine methyltransferase is a zinc metalloenzyme, and the homocysteine-binding domain of methionine synthase also carries a zinc site. Low zinc slows the reactions that consume methylfolate.

Folic acid must be reduced by dihydrofolate reductase, a step with limited capacity, and unreduced folic acid then competes with methylfolate for folate receptors and binding proteins. Supplying both in one formula means the two forms compete rather than add.

Making creatine in the body consumes a large share of available S-adenosylmethionine methyl groups. Supplying creatine directly lowers that draw, leaving more methyl capacity for other reactions the folate cycle supports.

Reduced folates oxidise readily, and ascorbate holds them in the reduced state in solution and in the gut. This is long-standing practice for keeping folate potency in a blend.

The enzyme that makes 5-methyltetrahydrofolate in the body is NADPH-dependent, and niacin supports the pyridine nucleotide pool that supplies NADPH. Taking methylfolate bypasses that step by supplying the product directly, which is the whole point of the form. The relationship is settled enzymology and explains what the supplement does and does not need.

One-carbon metabolism has two exits for homocysteine: remethylation to methionine, which needs folate and B12, and transsulfuration to cysteine, which needs PLP twice. Supplying methylfolate pushes the remethylation arm without touching the other one. Established cofactor pharmacology, and the reason B6 sits alongside folate in one-carbon formulas.

5-methyltetrahydrofolate exists chiefly to hand its methyl group to homocysteine, regenerating methionine. Added methionine feeds the same cycle from the product side and also raises homocysteine transiently as it is used. The cycle relationship is textbook; the practical effect of adding methionine to methylfolate has not been studied as a pair.

Converting methionine to S-adenosylmethionine consumes ATP, and ATP-utilising enzymes require magnesium as the counter-ion for the nucleotide. Methylation capacity therefore depends on magnesium as well as on methyl group supply. This is general enzymology rather than a folate-specific finding, and no combination study exists.

Homocysteine can be remethylated, which is where methylfolate acts, or committed to cysteine and then glutathione. Supplying cysteine directly reduces the demand for that second route. The two therefore work on the same node from opposite sides. Mechanistically established; nothing has tested the pair for a homocysteine endpoint, and homocysteine is a marker rather than an outcome.

The transsulfuration route converts homocysteine through cystathionine to cysteine using two PLP-dependent enzymes. Cysteine availability is the downstream measure of that route working. Established pathway biochemistry, stated as pathway structure and not as a measured combined effect.

Taurine sits two steps beyond homocysteine on the transsulfuration branch, so it is downstream of the same node methylfolate acts on from the other direction. Supplying it spares cysteine for other uses. Pathway reasoning, no combination data.

The PEMT route is one of the largest single drains on S-adenosylmethionine in the body, which is why choline and folate status are linked. Supplying preformed phosphatidylcholine reduces the methyl demand of that pathway, leaving methyl groups for other methyltransferases. Established biochemistry of the choline-folate interaction, not a tested supplement pair.

Catecholamine synthesis from tyrosine requires BH4, and BH4 regeneration is linked to folate status because 5-MTHF can reduce the quinonoid dihydrobiopterin intermediate. That link is why methylfolate appears in formulas alongside monoamine precursors. The biochemistry is established; the clinical consequence of combining them has not been measured, and the human methylfolate literature here is small and mostly in a mood context.

Both monoamine-forming hydroxylases share the BH4 cofactor whose regeneration is folate-linked, which is the mechanistic argument behind pairing methylfolate with a serotonin precursor. Carmon 2024 and Siddique 2025 report L-methylfolate given in mood and sleep contexts rather than combined with tryptophan, so the pair itself is untested. Precursor loading also has its own dose considerations.

Because 5-HTP is already hydroxylated, it does not require the BH4-dependent enzyme that links serotonin synthesis to folate. That makes the two less complementary than a tryptophan pairing would be, and the overlap is worth stating rather than assuming addition. Neither has been tested with the other, and 5-HTP carries its own interaction considerations with serotonergic medicines.

Dihydrofolate reductase is required to convert folic acid and dihydrofolate into usable reduced folates, and catechins inhibit it in laboratory assays. Methylfolate is already fully reduced and methylated, so it is less exposed to that step than folic acid is, which is a genuine mechanistic difference between the two forms rather than a ranking of them. The inhibition is an in vitro finding and its size at dietary catechin intakes in people is unestablished.

Borges-Vieira 2023 is a systematic review of B vitamins and vitamin D therapy in low mood and anxiety symptoms, which is where this pairing comes from. The two act by entirely separate mechanisms, one in one-carbon transfer and one through nuclear receptor signalling, so the pairing is empirical rather than mechanistic. The review is mentions-only for methylfolate specifically.

Melatonin is synthesised from serotonin by two enzymes, and serotonin synthesis is BH4-dependent and therefore folate-linked, which is a route by which folate status could touch sleep-related chemistry. Carmon 2024 reports on L-methylfolate and sleep parameters in adults with reduced MTHFR activity, which supports the interest without testing melatonin alongside it. Early confidence, and the endpoint is a sleep measure in a small selected group.

The two appear together in the same formulation category and act through unrelated mechanisms, inositol as a phosphoinositide signalling precursor and methylfolate in one-carbon transfer. This is formulation practice rather than a studied interaction. Nothing in the candidate set tests the pair.

Iron is needed for haem synthesis while folate supplies the thymidylate and purine synthesis that dividing erythroid precursors depend on. The two support normal red cell production through separate, non-substitutable routes, which is why they are co-formulated. Established haematological biochemistry; the pairing is not a claim that either corrects a deficiency of the other.

The glycine cleavage system generates methylene-tetrahydrofolate and requires a lipoamide-carrying H-protein, which puts lipoic acid chemistry directly in the mitochondrial one-carbon supply line. Lipoate for that protein is synthesised endogenously rather than taken from the diet, so the practical relevance of supplemental alpha-lipoic acid to this step is uncertain. Stated as a pathway link at promising confidence for that reason.

Folate interconversions are redox reactions running on NADPH, so the pyridine nucleotide pool sits underneath them. Separately, NAD-consuming methyltransferase substrates such as nicotinamide are themselves methylated using SAM, which draws on the same methyl pool methylfolate replenishes. That second link is the more concrete one, and it means high nicotinamide intakes and methyl group supply are connected in both directions.

Clearing nicotinamide requires methylation to N1-methylnicotinamide, and the methyl group comes from SAM. High nicotinamide intakes therefore draw on the same methyl pool that folate-dependent remethylation supplies. This is settled biochemistry and is the reason methyl donor status is discussed alongside large niacinamide doses; the size of the draw at ordinary supplement doses is not the same as at gram-level intakes.